Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.

INTRODUCTION: Bone loss is a major issue in patients affected by Duchenne muscular dystrophy (DMD), a rare musculoskeletal disorder, particularly in those treated with glucocorticoids (GCs). We aimed to assess the effectiveness of neridronate in terms of bone mineral density (BMD) changes in this population.
METHODS: We retrospectively reviewed the records of patients affected by DMD receiving GCs referred to our outpatient from 2015 to 2020. All patients were treated with an intramuscular (IM) injection of neridronate (25 mg every month). Bone density was measured at the lumbar spine (LS; L1-L4 tract) using dual-energy x-ray absorptiometry (DXA) (GE Lunar), no more than 4 weeks before (T0) and after 1 year from neridronate treatment (T1).
RESULTS: Eight boys with DMD were included with a mean age at diagnosis of 4.75 ± 2.81 years. Six of them were non-ambulant and two of them had previous low-trauma fractures (a distal femur fracture and a vertebral compression fracture, respectively). All patients were receiving deflazacort [median duration of therapy 11.5 years (interquartile range 2-25)]. At the DXA evaluation (T0), the mean L1-L4 BMD value was 0.716 ± 0.164 g/cm2. Six patients (75%) showed an L1-L4 Z-score height-adjusted of less than - 2. The mean age of neridronate initiation was 18.87 ± 6.81 years. All patients were supplemented with calcium carbonate and vitamin D at baseline. After 12 months of treatment (T1), the mean L1-L4 BMD value was 0.685 ± 0.190 g/cm2. Seven patients (87.5%) showed an L1-L4 Z-score of less than - 2. Changes in LS BMD and Z-score were not significant between T0 and T1 in our cohort (p = 0.674 and p = 0.208, respectively) as well as among non-ambulant patients with DMD without previous fragility fractures.
CONCLUSIONS: In this study, we reported for the first time that neridronate may slow bone loss in GC-treated patients with DMD at 1-year follow-up.

Key Summary Points

Introduction

Duchenne muscular dystrophy (DMD) is a rare X-linked neuromuscular disease (NMD), affecting about 1 on 6000 live male births [1], characterized by progressive muscle weakness, up to loss of independent ambulation by the age of 13 years old [2]. This disabling condition has several consequences on musculoskeletal health, including reduced bone density and strength and increased risk of fragility fractures. Bone loss in people with DMD depends on mechanical and biochemical mechanisms. Muscle weakness and progressive mobility loss are major culprits for poor mechanical stimulation of bone tissue causing reduced bone mineral density (BMD) [3]. Chronic muscle inflammation, observed in these patients, adversely affects signalling pathways that modulate muscle–bone cross talk [4]. In particular, several cytokines (i.e., interleukin-6, leukemia inhibitory factor), osteokines (i.e., osteopontin), and myokines (fibroblast growth factor 21, FGF21) are upregulated in patients with DMD contributing to bone loss [4]. Furthermore, destabilization of the dystrophin-associated protein complex (DAPC) and structural changes in the elastic properties of the myotendinous junctions reduced force transmission and mechanical stimuli on bone tissue [5].

Finally, although glucocorticoids (GCs) still represent the first-line intervention for delaying the decline of motor development in patients with DMD, their chronic use is associated with poor bone strength, as a consequence of impaired bone formation and mineralization of trabecular bone [6, 7]. Among GCs, deflazacort was considered less detrimental to the trabecular bone than prednisone [8], although recent studies have demonstrated that patients with DMD on daily deflazacort have a 16-fold increased risk for the first fragility fracture during 4 years of treatment [9]. Moreover, a new first-in-class steroidal anti-inflammatory drug, vamolorone, had recently shown a similar efficacy in maintaining muscle strength and physical performance with an improvement in bone turnover markers compared to the standard GC treatment in this population, along with a favorable safety profile, in terms of lack of stunting of growth [10].

To date, primary prevention of fragility fracture in this population includes supplementation of vitamin D with or without calcium, and physical activity [11]. Anti-osteoporotic drugs, such as bisphosphonates (BPs), are widely used in both primary and secondary osteoporosis, including glucocorticoid-induced osteoporosis (GIO). However, limited evidence supports their use in patients with DMD, except for those with previous vertebral or long-bone fragility fractures [12]. It is key to note that BP administration may affect the outer shape and inner structure of the growing metaphysis [13], justifying the limited use of these drugs in children.

Among available BPs, neridronate, a nitrogen-containing BP requiring parenteral administration, is effective and safe for patients with osteoporosis, including those affected by thalassemia-related bone loss. Moreover, this drug is effective in managing other conditions, such as complex regional pain syndrome type I, where localized bone loss is only one of the typical clinical findings [14-17].

This study aimed to assess the effectiveness of neridronate in terms of BMD changes in patients affected by DMD receiving GCs.

Methods

In this retrospective cohort study, we reviewed the records of patients with a genetic diagnosis of DMD receiving GCs from at least 3 months, referred to our outpatient for the management of bone fragility. Patients treated with neridronate received an intramuscular (IM) dose of 25 mg every month [18] and daily vitamin D (600 IU) and calcium supplementation (500 mg) [19]. We excluded medical records of patients aged less than 5 years old, treated previously with BPs, with severe scoliosis that may hinder instrumental acquisition and/or with any severe comorbidities (including cardiological and respiratory ones).

Our data collection included demographic, anthropometric, and anamnestic details such as age, body mass index (BMI), disease duration, and GC therapy, both as dose and duration. We included only patients that underwent dual-energy x-ray absorptiometry (DXA) measurements at our outpatient clinic. We reviewed DXA-derived (GE Lunar i-DXA) measurements of BMD at lumbar spine (LS), LS Z-score height-adjusted as recommended by the International Society for Clinical Densitometry (ISCD), as well as lateral vertebral assessment (LVA) to identify vertebral fragility fractures (VFx) performed no more than 4 weeks before (T0) and after 1 year from neridronate treatment (T1). Moreover, we provided DXA measurements performed before T0, where available.

The research was conducted in accordance with the Declaration of Helsinki and all patients signed an informed consent to provide available data for this study.

Statistical analysis was carried out using Statistical Package for the Social Sciences 25 (SPSS 25) software. Distribution of all variables was tested using Shapiro–Wilk test. Intergroup comparisons were made using Wilcoxon-Mann–Whitney test for data not normally distributed. A p value ≤ 0.05 was considered significant. Continuous variables are presented as mean ± standard deviation (SD) or median (IQR, interquartile range), and categorical variables as counts and percentage (%).

Results

A flowchart of study population selection is shown in Fig. 1. Medical records of eight boys with DMD are reported in Table 1. All patients received deflazacort at dosage of 15 mg/daily. At the DXA evaluation (T0), the mean L1–L4 BMD value was 0.716 ± 0.164 g/cm2. Six patients (75%) showed an L1–L4 Z-score of less than − 2. The mean age of neridronate initiation was 18.87 ± 6.81 years. After 12 months of treatment (T1), the mean L1–L4 BMD value was 0.685 ± 0.19 g/cm2. Seven patients (87.5%) showed an L1–L4 Z-score of less than − 2. No incident VFx at LVA and no new long-bone fractures referred by the patient were reported at T1. Moreover, no worsening of the previous VFx was observed at LVA evaluation. As shown in Table 2, changes in LS BMD and Z-score were not significant between T0 and T1 (p = 0.674 and p = 0.208, respectively). We performed a sub-analysis among the non-ambulant patients without previous fracture to identify changes in LS BMD and Z-score between baseline and T1. We observed that also in this population BMD changes were not significant (p = 0.917 and p = 0.249, respectively). Clinical and densitometric characteristics of five patients of our cohort that underwent at least three densitometric exams through our facility and relative comparisons are described in Table 3.

Fig. 1

Flowchart of study population selection

Table 1

Demographic and clinical characteristics of the study population

Variable	Patients with DMD (N = 8)
Age (years)	18.87 ± 6.81
Age at diagnosis (years)	4.75 ± 2.81
BMI (kg/m2)	23.31 ± 5.22
Duration GC therapy (years)	11.5 (2–25)
Functional status
Ambulant (%)	2 (25%)
Non-ambulant (%)	6 (75%)
Previous fractures
Vertebral (%)	1 (12.5%)
Long-bone (%)	1 (12.5%)

All variables were normally distributed. Continuous variables are expressed as mean ± standard deviation or median (IQR, interquartile range); discrete ones are expressed as total number (%)

DMD Duchenne muscular dystrophy, BMI body mass index, GC glucocorticoid

Table 2

Comparison between mean lumbar BMD and HA Z-score values among our DMD cohort (n = 8) and in the subgroup non-ambulant without previous fractures (n = 4)

DXA	BMD T0	BMD T1	p value	Z-score T0	Z-score T1	p value
L1–L4 (n = 8)	0.716 ± 0.16	0.685 ± 0.19	0.674	– 2.19 ± 0.76	– 2.49 ± 0.67	0.208
L1–L4 sub-group (n = 4)	0.756 ± 0.15	0.700 ± 0.21	0.917	– 2.08 ± 0.87	– 2.44 ± 0.73	0.249

Values are expressed as mean ± standard deviation

BMD bone mineral density, HA height-adjusted, DMD Duchenne muscular dystrophy, DXA dual-energy x-ray absorptiometry

Table 3

Case series of patients with DMD undergoing at least three densitometric exams at our facility

Patient	BMI (kg/m2)	Age at diagnosis (years)	Age at GC start (years)	Ambulant (Y/N)	Previous fractures (site)	L1–L4 BMD (g/cm2)a	L1–L4 BMDT0 (g/cm2)	p value	L1–L4HA Z-scorea	L1–L4HA Z-scoreT0	p value	L1–L4 BMDT0 (g/cm2)	L1–L4 BMDT1 (g/cm2)	p value	L1–L4HA Z-scoreT0	L1–L4 HA Z-score T1	p value
1	21.6	4	4	Y	–	0.644	0.706		– 2.66	– 2.35		0.706	0.785		– 2.35	– 2.14
2	24.22	4	4	N	–	0.804	0.748		– 2.6	– 3.1		0.748	0.822		– 3.1	– 2.4
3	31.09	5	8	N	Diaphyseal femur	0.532	0.599		– 1.7	– 2.28		0.599	0.66		– 2.28	– 3.24
4	15.17	2	5	N	–	0.688	0.678		– 2.25	– 2.47		0.678	0.681		– 2.47	– 2.86
5	18.84	9	9	N	L4	0.979	0.982b		– 1.9	– 1.3b		0.982b	0.796b		– 1.3b	– 2.7b
Mean value and standard deviation of DXA exams						0.730 + 0.17	0.742 + 0.14	0.500	– 2.23 + 0.43	– 2.30 + 0.64	0.893	0.742 + 0.14	0.748 + 0.07	0.500	– 2.30 + 0.64	– 2.66 + 0.42	0.345

DMD Duchenne muscular dystrophy, BMI body mass index, GC glucocorticoid, L lumbar, BMD bone mineral density, HA height-adjusted

aDensitometric values obtained 1 year before neridronate initiation

bThese values refer to L1–L3 score according to the International Society for Clinical Densitometry (ISCD) official positions

Discussion

In this study, we demonstrated that neridronate may slow the decline of BMD in patients with DMD receiving GCs. It has been reported that GC regimen and ambulatory status are independently associated with a significantly increased hazard ratio of first fragility fracture in this population [9]. In particular, loss of mobility with full-time wheelchair use is considered a risk factor of first fracture (greater than 75%) for every 3 months [20]. According to our data, no new fracture was reported among the four non-ambulant patients with DMD in the 12-month follow-up period.

Long-term GC therapy strongly contributes to low BMD and increased risk of VFx in patients with DMD [21]. Mayo et al. demonstrated a significant reduction in LS BMD Z-scores within the first 2 years of deflazacort therapy among boys with DMD, and this decline was consistent with subsequent years of therapy as well as with the loss of ambulation [8]. In our cohort, 1 year of neridronate administration did not significantly change LS BMD and Z-score, suggesting that this intervention may prevent bone loss in GC-treated patients with DMD. Moreover, the effectiveness of neridronate is confirmed also in non-ambulant patients, where LS BMD and Z-score did not significantly change. These results demonstrate how neridronate might mitigate BMD reduction also among patients with DMD with mobility loss.

Our findings are in line with those recently reported by Ronsley et al. in a retrospective, comparative effectiveness study [22]. They demonstrated that boys with DMD receiving intravenous (IV) administration of pamidronate or zoledronic acid had significantly lower mean decline of total-body and left hip BMD Z-scores compared to the untreated group (− 0.63 SD, p = 0.026, and − 1.04 SD, p = 0.004, respectively). It is key to note that our study provides data about BMD changes in a specific site (lumbar vertebrae) that is affected during GIO and DMD. Consistent with our findings, a recent randomized controlled trial assessing effects of five zoledronic acid infusions on BMD in patients with DMD showed higher BMD value in the treated arm versus control arm both at 12 and 24 months (both p < 0.001) [23].

Several guidelines recommend BPs use, both oral and parenteral, to treat GIO [24, 25].

In the last two decades, the benefits of BPs, in different formulations (IV or oral), in terms of BMD changes in patients with DMD have been thoroughly investigated [26]. Nevertheless, no study addressed the effectiveness of neridronate in patients affected by DMD receiving GCs.

Neridronate has a good safety profile, except for some cases of flu-like symptoms that resolved within a few days [27]. In an open-label 3-year study that assessed safety of neridronate in children and adolescents with osteogenesis imperfecta (OI), no fatal event was registered, and serious adverse events were considered not treatment-related; moreover, no cases of osteonecrosis of the jaw or atypical femur fracture were reported [28].

Considering the efficacy and safety of neridronate in children affected by idiopathic juvenile osteoporosis (IJO) or secondary osteoporosis [14, 29, 30], our data might support a role of this drug in the prevention of bone fragility in patients with DMD.

Concerning the efficacy of BPs in the secondary prevention of fragility fractures in patients with DMD treated with GCs, several studies [22, 26, 31] showed that these drugs reduce the number and severity of incident vertebral fractures, and pain after 2 years of therapy.

In this population, fragility fractures occur in about 20–40% of cases in comparison to less than 5% reported in healthy children [32]. The risk of at least one fracture, particularly of the spine and long bones, reaches 60% in patients with DMD aged 15 years [21]. The incidence of VFx is even higher in children with DMD on chronic GCs therapy [33, 34]. In our cohort of long-term GC-treated patients with DMD, no fracture was reported at 1-year follow-up (both at LVA evaluation and as referred by our population).

The main strength of our study is to have focused our investigations on the most commonly involved skeletal site in patients affected by DMD, particularly in those receiving GCs.

The main limitations of our study are the retrospective design with a low number of participants, 1-year follow-up, and the lack of a matched control population. In addition, we did not provide data about serum and urinary bone turnover markers during the 12 months of treatment. Finally, only LVA without radiographic imaging was available for the assessment of VFx. Despite these limitations, our data are noteworthy because we first described the effectiveness of the only BP (i.e., neridronate) already approved by the Italian national regulatory agency (AIFA) for the prevention and treatment of fragility fractures in the pediatric population (i.e., OI), in the management of bone loss in patients with DMD receiving GCs.

Conclusions

Our study suggests that IM administration of neridronate might slow the decline of bone loss at LS in boys with DMD receiving GCs. Moreover, after 1 year of treatment, no patient reported incident VFx. Further studies with long-term follow-up should be performed to confirm our findings.

In Duchenne muscular dystrophy (DMD), progressive muscle weakness and chronic use of glucocorticoids (GCs) cause poor bone health and increased risk of fragility fractures.

To date, bisphosphonates (BPs) may represent a therapeutic strategy, although limited evidence supports their use in this population.

Neridronate, a parenteral BP, demonstrates efficacy and safety in the management of secondary osteoporosis.

In this study, we assess the effectiveness of neridronate in the management of bone health in patients with DMD, treated with chronic GCs.

After 1 year of treatment, no changes in bone mineral density at the lumbar spine, as well as no incident vertebral fractures, were observed in our population.

Further well-designed trials are required to confirm the role of neridronate in the prevention of bone fragility in patients with DMD receiving chronic GCs.